Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake

Journal of Nuclear Medicine

Volumn 46, Issue 10, 2005, Pages 1753-1759

  Lee, Jong Doo ^a   Yang, Woo Ick ^a   Park, Young Nyun ^a   Kim, Kyung Sik ^a   Choi, Jin Sub ^a   Yun, Mijin ^a   Ko, Dooheun ^a   Kim, Tae Sung ^a   Cho, Arthur E H ^a   Kim, Hye Mi ^a   Han, Kwang Hyub ^a   Im, Seung Soon ^a   Ahn, Yong Ho ^a   Choi, Chang Woon ^b   Park, Jeon Han ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

18F FDG; Cholangiocarcinoma; Glucose metabolism; Hepatocellular carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; HEXOKINASE 3; HEXOKINASE ISOENZYME; PENTOSE PHOSPHATE; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BILE DUCT CARCINOMA; CALCULATION; CARBOHYDRATE METABOLISM; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; GEL; GLUCONEOGENESIS; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; BILE DUCT TUMOR; CELL CULTURE; COMPARATIVE STUDY; INTRAHEPATIC BILE DUCT; METABOLISM; METHODOLOGY; SCINTISCANNING;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLYCOLYSIS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TUMOR CELLS, CULTURED;

EID: 33644613007     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808.
2. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
3. 11C-Acetate PET imaging in hepatocellular harcinoma and other liver masses. J Nucl Med. 2003;44:213-222.
4. 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467-1472.
5. Lee JD, Yun M, Lee JM, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to F-18-FDG uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1621-1630.
6. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
7. Roh MS, Jeong JS, Kim YH, Kim MC, Hong SH. Diagnostic utility of GLUT 1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology. 2004; 51:1315-1318.
8. Zimmerman RL, Fogt F, Burke M, Murakata LA. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular- carcinoma. Oncol Rep. 2002;9:689-692.
9. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: isolation, sequence, and activity of the promotor type II hexokinase. J Biol Chem. 1995;270:16918-16925.
10. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol. 2004;40:298-304.
11. Bradford NM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
12. Oakley BR, Kirsch DR, Morris NR. A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels. Anal Biochem. 1980;105:361-363.
13. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins in silver-stained polyacrylamide gels. Anal Chem. 1996;68:850-858.
14. Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: Un amour impossible? Electrophoresis. 2000;21:1054-1070.
15. Larson SM. Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerating glucose metabolism. Clin Cancer Res. 2004;10:2203-2204.
16. Wong MS, Raab RM, Rigoutsos I, Stephanopoulos GN, Kelleher JK. Metabolic and transcriptional patterns accompanying glutamine depletion and repletion in mouse hepatoma cells: a model for physiological regulatory networks. Physiol Genomics. 2004;16:247-255.
17. Bode BP, Fuchs BC, Hurley BP, et al. Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1062-G1073.
18. Hansson PK, Asztely AK, Clapham JC, Schreyer SA. Glucose and fatty acid metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: responsiveness to nutrient availability. Biochim Biophys Acta. 2004;1684:54-62.
19. Wilson JE. Isozymes of mammalian hexokinases: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049-2057.
20. Goel A, Mathupala SP, Pedersen PL. Glucose metabolism in cancer: evidence that methylation events play a role in activating type II hexokinase gene expression. J Biol Chem. 2003;278:15333-15340.
21. Klimek F, Bannasch P. Isozyme shift from glucokinase to hexokinase is not an early but a late event in hepatocarcinogenesis. Carcinogenesis. 1993;14:1857-1861.
22. m hexokinase is expressed in the mhAT3F hepatoma cell line. J Biol Chem. 1998;273:26187-26193.
23. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neuman RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59:4709-4714.
24. Rempel A, Mathupala SP, Pedersen PL. Glucose catabolism in cancer cells: regulation of the type II hexokinase promoter by glucose and cyclic AMP. FEBS Lett. 1996;385:233-237.
25. Parry DM, Pedersen PL. Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor: evidence for an outer mitochondrial membrane location. J Biol Chem. 1983;258:10904-10912.
26. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2003; 277:7610-7618.
27. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 2003;23:7315-7328.
28. Majewski N, Nogueira V, Robery RB, Hay N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol. 2004;24:730-740.
29. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892-3899.
30. Hacker HJ, Sreingerg P, Toshkov I, Oesch F, Bannasch P. Persistence of cholangiocellular and hepatocellular lesions observed in rats fed a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis. 1992;13:271-276.
31. Frederiks WM, Bosch KS, De Jong JSSG, Van Noorden CJF. Post-translational regulation of glucose-6-phosphate dehydrogenase activity in (pre)neoplastic lesions in the rat liver. J Histochem Cytochem. 2003;51:105-112.
32. Fratelli M, Demol H, Puype M, et al. Identification by redox proteomics of glutathionylated proteins in oxidative-stressed human T lymphocytes. Proc Natl Acad Sci USA. 2002;99:3505-3510.
33. Hammond KD, Balinsky D. Activities of key gluconeogenic enzymes and glycogen synthase in rat and human livers, hepatomas, and hepatoma cell cultures. Cancer Res. 1978;38:1317-1322.
34. Liao J, Barthel A, Nakatani K, Roth RA. Activation of protein kinase B/Akt is sufficient to repress the glucocorticoid and cAMP induction of the phosphoenolpyruvate carboxykinase gene. J Biol Chem. 1998;273:27320- 27324.
35. Dang CV, Semenza GL. Oncogenic alteration of metabolism. Trends Biochem Sci. 1999;24:68-72.